BioSpace News Archive

Janux Therapeutics, Inc. today announced interim Phase 1 clinical data for PSMA-TRACTr JANX007 in adult subjects with metastatic castration-resistant prostate cancer (mCRPC) and provided a pipeline update.

Sangamo Therapeutics, Inc. today announced it has signed an evaluation and option agreement with Prevail Therapeutics through which Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets.

Cognito Therapeutics today announced robust lobe-specific changes in white matter volume and myelination in Alzheimer’s Disease (AD) patients following six-months of non-invasive gamma stimulation therapy using the at-home wearable device.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that they have entered into a definitive agreement for the sale of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings.

LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW) today announced that a recently posted article in BioRxiv ( https://www.biorxiv.org/content/10.1101/2023.07.12.548685v1 ), based on the results of a collaboration between the Company and the Netherlands Cancer Institute, shows that inhibition of PP2A in colon cancer cells, using LIXTE’s lead clinical compound LB-100, leads to major changes in the way cancer cells process their mRNAs.

Beckman Coulter Diagnostics today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

NeuroSense Therapeutics Ltd. today announced it will host an investor conference at its U.S. office in Cambridge, Massachusetts on Monday, July 24, 2023 from 8:30 AM- 10:15 AM.

CSL Seqirus, a business of CSL, announced it has begun to ship its portfolio of innovative cell-based, adjuvanted and egg-based influenza vaccines across the U.S. in preparation for the 2023/24 influenza season.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive topline results from the Phase 3 PAPILLON study evaluating RYBREVANT® in combination with chemotherapy in patients with newly diagnosed advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

ThinkCyte today announced a strategic research partnership with the Institute for Molecular Medicine Finland (FIMM-HiLIFE), University of Helsinki aimed at advancing the understanding of leukemia and its treatment.